Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,279,889 B2 for its innovative catheter-based platform technology. The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation procedures.
The technology features a catheter-based microchip sensing array antenna designed to detect neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. Key applications include chronic pain management, hypertension treatment, and cardiac modulation. The company plans to submit an IDE and begin U.S. clinical trials in 2025 for pancreatic cancer pain treatment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.